The Phase III Destiny-Breast04 trial showed survival benefit of patients with HER2 low metastatic breast cancers, including a small number of TNBC populations, treated with the antibody drug conjugate trastuzumab deruxtecan (T-DXd) compared to chemotherapy [20]. The gene discussed is ERBB2; the disease is breast carcinoma.